Monthly Campaign Webinar

January 16, 2019
Today’s Webinar

• Together 2 Goal® Updates
  – Webinar Reminders
  – AMGA Annual Conference 2020
  – New Partnership: Endocrine Society
  – National Day of Action Wrap Report
  – Lives Improved

• American Diabetes Association 2020 Standards of Care
  – Eric L. Johnson, M.D. of University of North Dakota School of Medicine and Health Sciences

• Q&A
  – Use Q&A or chat feature
Webinar Reminders

• Webinar will be recorded today and available the week of January 20th
  – www.Together2Goal.org

• Participants are encouraged to ask questions using the “Chat” and “Q&A” functions on the right side of your screen
AMGA Annual Conference 2020

March 25 – 28, 2020 in San Diego, California
amga.org/ac20

Shared Learning
Real-world case studies and insights from AMGA members, including Geisinger, Henry Ford Health System, Intermountain Healthcare, Mayo Clinic, and many others.

Networking
Join 2,000+ healthcare leaders for hours of free-flowing conversation and structured networking.

Inspiring Keynotes
This year’s agenda features future-focused Dr. Peter Diamandis, community health guru Dr. Toyin Ajayi, and viral sensation ZDoggMD.
New Partnership: Endocrine Society
National Day of Action Wrap Report

T2G Talk & Taste Group Events
Today’s Featured Presenter

Eric L. Johnson, M.D.

Associate Professor
University of North Dakota School of Medicine and Health Sciences
Assistant Medical Director
Altru Diabetes Center
Chair, ADA Primary Care Advisory Group
Updates on the American Diabetes Association Standards of Medical Care – 2020

Eric L. Johnson, M.D.
Associate Professor
University of North Dakota School of Medicine and Health Sciences
Assistant Medical Director
Altru Diabetes Center
Grand Forks, ND
DISCLOSURES

• PI/SubPI on many clinical trials at Altru Health System, Grand Forks, ND
• Speakers Bureau Novo Nordisk
• Speakers Bureau Medtronic
• Advisory Board Medtronic
• Advisory Board Sanofi
• Advisory Board Novo Nordisk
• American Diabetes Association speaker
• I have type 1 diabetes and use insulin
Acknowledgements

Slides adapted from American Diabetes Association and Nisa M. Maruthur, MD, MHS, Johns Hopkins University
OBJECTIVE

Describe changes in ADA Standards of Medical Care-2020 related to diagnosis and management of diabetes
• This slide deck is not meant to be comprehensive, but highlights important changes in the Standards of Care-2020

• I will draw your attention to important changes and summarize some of these changes
Standards of Medical Care in Diabetes—2020
The Standards.

Intended to provide clinicians, patients, researchers, payers, and other interested individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care.
• Search of scientific diabetes literature over past year
• Recommendations revised per new evidence

• Professional Practice Committee
• Reviewed by ADA’s Board of Directors
• Living Standards

• Funded out of ADA’s general revenues
• Does not use industry support
Improving Care and Promoting Health in Populations.

Additional information was included on the rising cost of medications, particularly insulin.

A new section “Migrant and Seasonal Agricultural Workers” was added to discuss the challenges of managing type 2 diabetes specific to this group.
Classification and Diagnosis of Diabetes

A new recommendation (2.8) was added regarding testing for prediabetes and/or type 2 diabetes for women with overweight or obesity and/or who have one or more additional risk factors for diabetes who are planning a pregnancy.

The “Gestational Diabetes Mellitus” (GDM) section was revised, and the two-step approach for screening and diagnosing GDM no longer includes National Diabetes Data Group criteria.
Are you at risk for type 2 diabetes?

### Diabetes Risk Test:

<table>
<thead>
<tr>
<th>1. How old are you?</th>
<th>WRITE YOUR SCORE IN THE BOX.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 40 years (0 points)</td>
<td>4' 10&quot; 119-142</td>
</tr>
<tr>
<td>40-49 years (1 point)</td>
<td>5' 1&quot; 132-157</td>
</tr>
<tr>
<td>50-59 years (2 points)</td>
<td>5' 2&quot; 136-163</td>
</tr>
<tr>
<td>60 years or older (3 points)</td>
<td>5' 3&quot; 141-169</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Are you a man or a woman?</th>
<th>( \sum )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Man (1 point)</td>
<td>5' 4&quot; 140-173</td>
</tr>
<tr>
<td>Woman (0 points)</td>
<td>5' 5&quot; 150-179</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. If you are a woman, have you ever been diagnosed with gestational diabetes?</th>
<th>( \sum )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1 point)</td>
<td>5' 6&quot; 155-185</td>
</tr>
<tr>
<td>No (0 points)</td>
<td>5' 7&quot; 159-190</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Do you have a mother, father, sister or brother with diabetes?</th>
<th>( \sum )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1 point)</td>
<td>5' 8&quot; 164-194</td>
</tr>
<tr>
<td>No (0 points)</td>
<td>5' 9&quot; 169-202</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. Have you ever been diagnosed with high blood pressure?</th>
<th>( \sum )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1 point)</td>
<td>5' 10&quot; 174-208</td>
</tr>
<tr>
<td>No (0 points)</td>
<td>5' 11&quot; 179-214</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. Are you physically active?</th>
<th>( \sum )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (1 point)</td>
<td>6' 1&quot; 188-220</td>
</tr>
<tr>
<td>No (0 points)</td>
<td>6' 2&quot; 194-232</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. What is your weight category?</th>
<th>( \sum )</th>
</tr>
</thead>
<tbody>
<tr>
<td>If you weigh less than the amount in the left column: 0 points</td>
<td></td>
</tr>
</tbody>
</table>

If you scored 5 or higher:

You are at increased risk for having type 2 diabetes. However, only your doctor can tell for sure if you do have type 2 diabetes or prediabetes, a condition in which blood glucose levels are higher than normal but not yet high enough to be diagnosed as diabetes. Talk to your doctor to see if additional testing is needed.

Type 2 diabetes is more common in African Americans, Hispanics/Latinos, Native Americans, Asian Americans, and Native Hawaiians and Pacific Islanders.

Higher body weight increases diabetes risk for everyone. Asian Americans are at increased diabetes risk at lower body weight than the rest of the general public (about 15 pounds lower).

---

Lower Your Risk

The good news is you can manage your risk for type 2 diabetes. Small steps make a big difference in helping you live a longer, healthier life.

If you are at high risk, your first step is to visit your doctor to see if additional testing is needed.

Visit diabetes.org or call 1-800-DIABETES (1-800-342-2383) for information, tips on getting started, and ideas for simple, small steps you can take to help lower your risk.
## Table 2.7—Screening for and diagnosis of GDM

**One-step strategy**

Perform a 75-g OGTT, with plasma glucose measurement when patient is fasting and at 1 and 2 h, at 24–28 weeks of gestation in women not previously diagnosed with diabetes. The OGTT should be performed in the morning after an overnight fast of at least 8 h. The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded:

- Fasting: 92 mg/dL (5.1 mmol/L)
- 1 h: 180 mg/dL (10.0 mmol/L)
- 2 h: 153 mg/dL (8.5 mmol/L)

**Two-step strategy**

**Step 1**: Perform a 50-g GLT (nonfasting), with plasma glucose measurement at 1 h, at 24–28 weeks of gestation in women not previously diagnosed with diabetes. If the plasma glucose level measured 1 h after the load is ≥130, 135, or 140 mg/dL (7.2, 7.5, or 7.8 mmol/L, respectively), proceed to a 100-g OGTT.

**Step 2**: The 100-g OGTT should be performed when the patient is fasting. The diagnosis of GDM is made when at least two* of the following four plasma glucose levels (measured fasting and at 1, 2, and 3 h during OGTT) are met or exceeded (Carpenter-Coustan criteria [154]):

- Fasting: 95 mg/dL (5.3 mmol/L)
- 1 h: 180 mg/dL (10.0 mmol/L)
- 2 h: 155 mg/dL (8.6 mmol/L)
- 3 h: 140 mg/dL (7.8 mmol/L)

GDM, gestational diabetes mellitus; GLT, glucose load test; OGTT, oral glucose tolerance test. *American College of Obstetricians and Gynecologists notes that one elevated value can be used for diagnosis (150).
Prevention or Delay of Type 2 Diabetes

Additional resources and information were added regarding the National Diabetes Prevention Program, Medicare Diabetes Prevention Programs, and the Centers for Disease Control (CDC) Diabetes Prevention Impact Tool Kit. More information was added on the risk reduction certain groups experienced with metformin use, based on 15-year follow-up data from the Diabetes Prevention Program Outcomes Study.
Lifestyle Interventions

3.2 Refer patients with prediabetes to an intensive behavioral lifestyle intervention program modeled on the Diabetes Prevention Program (DPP) to achieve and maintain 7% loss of initial body weight and increase moderate intensity physical activity (such as brisk walking) to at least 150 min/week. A

3.3 A variety of eating patterns are acceptable for persons with prediabetes. B
Pharmacologic Interventions

3.6 Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially for those with BMI $\geq 35$ kg/m$^2$, those aged $<60$ years, and women with prior gestational diabetes mellitus. A

3.7 Long-term use of metformin may be associated with biochemical vitamin B12 deficiency, and periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy. B
Facilitating Behavior Change and Well-being to Improve Health Outcomes

(formerly “Lifestyle Management.”)

The title of this section was previously “Lifestyle Management” and was changed to more appropriately emphasize how effective behavior management and psychological well-being are foundational to achieving treatment goals for people with diabetes.

The section “Nutrition Therapy” was updated to include guidance and evidence presented in “Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report” (https://doi.org/10.2337/dci19-0014), published in May 2019.
Facilitating Behavior Change and Well-being to Improve Health Outcomes

Because of the emerging evidence from the CDC on deaths related to e-cigarettes, more information was added discouraging their use.

Recommendations and supporting evidence on anxiety disorders, depression, disordered eating behavior, and serious mental illness previously found at the end of Section 4 were moved to Section 5 and are included under “Psychosocial Issues.” More information on psychosocial screening for social determinants of health and significant changes in life circumstances was also added.
Glycemic Targets

Based on the publication “Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range” (https://doi.org/10.2337/dci19-0028) published in June 2019, new recommendations (6.4 and 6.5) were added on use of the ambulatory glucose profile (AGP) report and time in range (TIR) for assessment of glycemic management. A discussion of AGP reports, time in range, and glucose management indicators follow the new recommendations. An example of an AGP report was also added (Fig. 6.1)

This section was modified to include a new discussion on the use of continuous glucose monitoring technology in hypoglycemia prevention.
## Glycemic Targets

### Standards of Medical Care in Diabetes - 2020.

**Diabetes Care** 2020;43(Suppl. 1):S66-S76

---

### AGP Report

<table>
<thead>
<tr>
<th>Date Range</th>
<th>Period Active</th>
<th>Time Active %</th>
</tr>
</thead>
<tbody>
<tr>
<td>26 Feb 2019-10 Mar 2019</td>
<td>13 days</td>
<td>99.9%</td>
</tr>
</tbody>
</table>

### Glucose Statistics and Targets

**Glucose Ranges**
- **Target Range** (70–180 mg/dL) — Greater than 70% (16h 48min)
- **Below 70 mg/dL** — Less than 4% (58min)
- **Below 54 mg/dL** — Less than 1% (14min)
- **Above 180 mg/dL** — Less than 25% (8h)
- **Above 250 mg/dL** — Less than 5% (1h 12min)

Each 5% increase in time in range (70–180 mg/dL) is clinically beneficial.

### Average Glucose
- **173 mg/dL**

### Glucose Management Indicator (GMI)
- **7.6%**

### Glucose Variability
- **49.5%**

Defined as percent coefficient of variation (%CV); target ≤36%

---

**Name**

**MRN**

**Time in Ranges**

- **Very High** (>250 mg/dL) — **20%** (4h 48min)
- **High** (181–250 mg/dL) — **23%** (5h 31min)
- **Target Range** (70–180 mg/dL) — **47%** (11h 17min)
- **Low** (54–69 mg/dL) — **4%** (58min)
- **Very Low** (<64 mg/dL) — **6%** (1h 28min)
Also new to “A1C and Cardiovascular Disease Outcomes” is the strategy to introduce sodium–glucose cotransporter 2 inhibitors (SGLT-2i) or glucagon-like peptide 1 (GLP-1) receptor agonists in patients with cardiovascular disease meeting A1C goals for cardiovascular benefit.
This section was reorganized into three broad categories titled “Self-Monitoring of Blood Glucose,” “Continuous Glucose Monitors,” and “Insulin Delivery.” Within these revised sections, emphasis has been made on how there is no “one-size-fits-all” approach to technology use in people with diabetes. Due to the rapidly changing field of diabetes technology, the recommendations in each category have been revised, and more evidence has been added to support the recommendations throughout.
Figure 9.1 has been revised to include the latest trial findings on GLP-1 receptor agonists and SGLT2 inhibitors. It now suggests that these drugs should be considered for patients when atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease predominates independent of A1C.

Figure 9.2 has been simplified to more easily guide providers through intensification to injectable therapies.
PHARMACOLOGIC APPROACHES TO GLYCEMIC TREATMENT

Glucose-lowering Medication in Type 2 Diabetes: Overall Approach

Pharmacologic Approaches to Glycemic Management: Standards of Medical Care in Diabetes - 2020. Diabetes Care 2020;43(Suppl. 1):S98-S110
Use principles in Figure 9.1, including reinforcement of behavioral interventions (weight management and physical activity) and provision of DSMES to meet individualized treatment goals.

If injectable therapy is needed to reduce A1C

Consider GLP-1 RA in most patients prior to insulin

**INITIATION:** Initiate appropriate starting dose for agent selected (varies within class)

**TITRATION:** Gradual titration to maintenance dose (varies within class)

If above A1C target

Add basal insulin

Choice of basal insulin should be based on patient-specific considerations, including cost. Refer to Table 9.3 for insulin cost information.

Add basal analog or bedtime NPH insulin

**INITIATION:** Start 10 IU a day OR 0.1-0.2 IU/kg a day

**TITRATION:**
- Set FPG target (see Section 6: Glycemic Targets)
- Choose evidence-based titration algorithm, e.g., increase 2 units every 3 days to reach FPG target without hypoglycemia
- For hypoglycemia determine cause, if no clear reason lower dose by 10-20%

If already on GLP-1 RA or if GLP-1 RA not appropriate OR insulin preferred
Intensifying to injectable therapies. DSMES, diabetes self-management education and support; FPG, fasting plasma glucose; FRC, fixed-ratio combination; GLP-1 RA, glucagon-like peptide 1 receptor agonist; max, maximum; PPG, postprandial glucose. Adapted from Davies et al. (33)
Pharmacologic Approaches to Glycemic Treatment (continued).

A discussion was added on access to analog insulins and how there are multiple approaches to insulin treatment, with the goal of keeping patients safe and avoiding diabetic ketoacidosis and significant hypo- or hyperglycemia.

New evidence and a recommendation (9.6) were added on early combination therapy for type 2 diabetes to extend the time to treatment failure based on findings from the VERIFY trial.

Discussion of REDUCE-IT was added to the section “Treatment of Other Lipoprotein Fractions or Targets,” and a new recommendation (10.31) was included on considering icosapent ethyl for reducing cardiovascular risk.

This section is endorsed for the second consecutive year by the American College of Cardiology.
Statin Treatment—Primary Prevention

10.19 For patients with diabetes aged 40–75 years without atherosclerotic cardiovascular disease, use moderate-intensity statin therapy in addition to lifestyle therapy. A

10.20 For patients with diabetes aged 20–39 years with additional atherosclerotic cardiovascular disease risk factors, it maybe reasonable to initiate statin therapy in addition to lifestyle therapy. C

10.21 In patients with diabetes at higher risk, especially those with multiple atherosclerotic cardiovascular disease risk factors or aged 50–70 years, it is reasonable to use high-intensity statin therapy. B

10.22 In adults with diabetes and 10-year ASCVD risk of 20% or higher, it may be reasonable to add ezetimibe to maximally tolerated statin therapy to reduce LDL cholesterol levels by 50% or more. C
Statin Treatment—Secondary Prevention

10.23 For patients of all ages with diabetes and ASCVD, high-intensity statin therapy should be added to lifestyle therapy. A

10.24 For patients with diabetes and ASCVD considered very high risk using specific criteria, if LDL cholesterol is $\geq 70$ mg/dL on maximally tolerated statin dose, consider adding additional LDL-lowering therapy (such as ezetimibe or PCSK9 inhibitor). A Ezetimibe may be preferred due to lower cost.

10.25 For patients who do not tolerate the intended intensity, the maximally tolerated statin dose should be used. E
10.26 In adults with diabetes aged >75 years already on statin therapy, it is reasonable to continue statin treatment. B

10.27 In adults with diabetes aged >75 years, it may be reasonable to initiate statin therapy after discussion of potential benefits and risks. C

10.28 Statin therapy is contraindicated in pregnancy. B
Cardiovascular Disease and Risk Management (continued).

Discussion of the trials CANVAS, CANVAS-Renal, CREDENCE, DECLARE-TIMI 58, REWIND, and CARMELINA were added to the section “Glucose-Lowering Therapies and Cardiovascular Outcomes.” The cardiovascular outcomes trials of available antihyperglycemic medications completed after the issuance of FDA 2008 guidelines table (Table 10.3) has been divided into three tables by drug class (Table 10.3A on DPP-4 Inhibitors; Table 10.3B on GLP-1 receptor agonists; and Table 10.3C on SGLT2 inhibitors)
Microvascular Complications and Foot Care

The recommendation on screening for chronic kidney disease (11.1) has been modified to include twice-yearly screenings for certain patients. A treatment recommendation (11.3) was modified to provide more detail on use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes and diabetic kidney disease. A new recommendation (11.5) was added about avoiding discontinuation of RAS blockade in response to minor increases in serum creatinine in the absence of volume depletion.

More findings were added from the Canagliflozin and Renal End points in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial.
Chronic Kidney Disease—Screening

11.1 At least once a year, assess urinary albumin (e.g., spot urinary albumin-to-creatinine ratio) and estimated glomerular filtration rate (eGFR) in patients with type 1 diabetes with duration of ≥5 years and in all patients with type 2 diabetes regardless of treatment. B

Patients with urinary albumin >30 mg/g creatinine and/or an eGFR <60 mL/min/1.73m² should be monitored twice annually to guide therapy. C
Screening for diabetic retinopathy recommendations (11.16 and 11.17) and supportive text were revised to include consideration of retinal photograph with remote reading or use of a validated assessment tool as a way to improve screening access.
Within the section “Neurocognitive Function,” more information was added on the importance of assessment for cognitive decline and impairment.

A new recommendation (12.14) urging providers to consider cost of care and insurance coverage when prescribing medications to older adults to reduce the risk of cost-related nonadherence was added to the section “Pharmacologic Therapy.” The GLP-1 receptor agonist and SGLT2 inhibitor discussions were expanded in this section as well.

A new section titled “Special Considerations for Older Adults With Type 1 Diabetes” was added to address the treatment of this growing population.
Management of Diabetes in Pregnancy.

Greater emphasis has been placed on preconception care for women with diabetes, and a recommendation (14.5) focusing on nutrition, diabetes education, and screening for diabetes related complications was added. A new table (Table 14.1) was also added on preconception education, medical assessment, and screening.

Recommendations (14.9–14.12) on use of continuous glucose monitors and measuring glycemia in pregnancy were added to the section “Glycemic Targets in Pregnancy” to provide more information on their utility.

The section “Postpartum Care” was expanded to include recommendations (14.16–14.22) and supporting evidence on postpartum insulin requirements, management of women with a history of GDM and risks of type 2 diabetes, and psychosocial assessment.
There are some women with GDM requiring medical therapy who, due to cost, language barriers, comprehension, or cultural influences, may not be able to use insulin safely or effectively in pregnancy. Oral agents may be an alternative in these women after a discussion of the known risks and the need for more long-term safety data in offspring. However, due to the potential for growth restriction or acidosis in the setting of placental insufficiency, metformin should not be used in women with hypertension, preeclampsia, or at risk for intrauterine growth restriction.

Further discussion has been added regarding when insulin may not be an option for some women with GDM, and how oral agents may play a role in treatment in certain circumstances:
Diabetes Care in the Hospital

New evidence was also added to the section “Preventing Admissions and Readmissions”
Case Study
Avoid therapeutic inertia

**Decision Cycle for Patient-centered Glycemic Management in Type 2 Diabetes**

- **GOALS OF CARE**
  - Prevent complications
  - Optimize quality of life

- **Review and Agree on Management Plan**
- **Assess Key Patient Characteristics**
- **Consider Specific Factors Which Impact on Choice of Treatment**
- **Ongoing Monitoring and Support**
- **Implement Management Plan**
- **Agree on Management Plan**
- **Shared Decision-Making to Create a Management Plan**
Case 1: MT

MT is a 58-year-old Hispanic female

T2DM x 11 years with dyslipidemia, HTN, albuminuria, non-painful peripheral neuropathy, obesity, non-alcoholic fatty liver disease (NAFLD), history of myocardial infarction (MI) 3 years ago

Current medications:

- Metformin 1000 mg orally twice a day
- Glipizide 10 mg orally once daily
- Pioglitazone 30 mg orally once daily
- Lisinopril 20 mg orally once daily
- Metoprolol XL 25 mg orally once daily
- Atorvastatin 80 mg orally once daily
- Aspirin 81 mg orally once daily
Case 1: MT

Physical exam
Nonproliferative retinopathy, normal heart and lung sounds, obese, decreased vibratory and filament sensation in otherwise healthy appearing feet

Concerns
Many blood sugars in 200-300s mg/dL, but occasionally less than 70 mg/dL
Fatigue
Difficulty losing weight
Urinary frequency

Labs
A1C 10.2%
Lipids in target range (on high intensity statin), serum creatinine 0.9 mg/dL, GFR 54 mL/minute/1.73 m², hepatic function revealing minor transaminase elevation, urine albumin 110 mg/24 hr (normal <30 mg/24 hr)

What next?
Case 1: MT

Recall current standards of care recommend a SGLT-2 inhibitor or a GLP-1 agonist in the patient with established cardiovascular disease.

One of patient's main complaints is difficulty losing weight, both of these drug classes are weight-neutral or may promote weight loss.

Basal insulin could also be considered here- A1C greater than 10% with symptoms.
Case 1: MT

Could do any of the following in the patient with established CVD

Add drug class: GLP-1 agonist
Add drug class: SGLT-2 inhibitor
Using both GLP-1 agonist or SGLT-2 inhibitor for maximal weight loss

Would definitely
Continue metformin (renal function is OK)
Refer to diabetes educator and dietician for interprofessional team care
Assess well-being/lifestyle factors

Would consider
Stop glipizide
Stop pioglitazone
Case 1: MT Summary

What if A1C was not at target in 3 months?

-if not on insulin yet, would definitely consider

Advance therapy, avoid clinical inertia

Remember appropriate interprofessional team-based diabetes self-management education and support
Standards of Care

Resources

• Full version available
• Abridged version for PCPs
• Free app, with interactive tools
• Pocket cards with key figures
• Free webcast for continuing education credit

Professional.Diabetes.org/SOC
Thank you!
February Webinar

- **Date/Time**: February 20, 2020 from 2-3pm Eastern
- **Topic**: Calculating Lives Improved and Leveraging Data
- **Presenter**: AMGA
Questions